Home Latest News TCT 2017: Artificial intelligence approach to cardiac imaging

TCT 2017: Artificial intelligence approach to cardiac imaging

TCT 2017: Artificial intelligence approach to cardiac imaging

Analytics 4 Life, a digital health company applying artificial intelligence to improve and develop existing care pathways, has announced it will be presenting new clinical data on the company’s ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium in Denver.

The initial results “suggest that our cardiac imaging technology has clinically significant utility in assessing coronary artery disease (CAD), without the need for radiation, exercise or pharmacologic stress,” the company’s CEO Don Crawford says.

“Conventional CAD detection pathways may be less accurate in specific populations, such as obese, elderly and female patients, but these early results show a promising potential for alternative technology.”

The CADLAD study is a two-stage clinical trial at 13 sites in the USA measuring the diagnostic performance of the company’s cardiac phase space tomography analysis (cPSTA) system in assessing cardiac health related to the presence of CAD.

The cPSTA System, or CorVista, is a non-invasive, physician-directed diagnostic test that uses a hand-held device to scan intrinsic signals from the body without radiation, contrast agents, or cardiac stress. The signal data is then transmitted to a secure, cloud-based repository for analysis, where it is analysed by a machine-learned algorithm to generate a unique image and a heart model indicating areas of potential heart disease associated with the presence of CAD. The results of the test are displayed on a secure physician web portal that, in combination with a patient’s medical history, risk factors, and symptoms, are used by the interpreting physician to recommend further treatment.

The ongoing study is designed to test the utility of cPSTA in a large population and other important subgroups. Enrolment into the study’s first stage, focused on product development, is complete with enrolment in the study’s second stage finishing before the end of this year. Results will be available early 2018 and will support the company’s US FDA regulatory application.

Thomas Stuckey (UNC School of Medicine, Cone Health Heart and Vascular Center Greensboro, USA) will be presenting two poster presentations and a lecture at the TCT 2017 scientific symposium on the 30th of October.


Please enter your comment!
Please enter your name here